JP2017523149A - エドキサバンの医薬組成物 - Google Patents

エドキサバンの医薬組成物 Download PDF

Info

Publication number
JP2017523149A
JP2017523149A JP2016574064A JP2016574064A JP2017523149A JP 2017523149 A JP2017523149 A JP 2017523149A JP 2016574064 A JP2016574064 A JP 2016574064A JP 2016574064 A JP2016574064 A JP 2016574064A JP 2017523149 A JP2017523149 A JP 2017523149A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
edoxaban
dosage form
group
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016574064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523149A5 (enExample
Inventor
ラネブルガー，ヨハンネス
ファールーク，ホッサム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of JP2017523149A publication Critical patent/JP2017523149A/ja
Publication of JP2017523149A5 publication Critical patent/JP2017523149A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016574064A 2014-08-06 2015-05-13 エドキサバンの医薬組成物 Pending JP2017523149A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180078.9 2014-08-06
EP14180078 2014-08-06
PCT/EP2015/060656 WO2016020080A1 (en) 2014-08-06 2015-05-13 Pharmaceutical compositions of edoxaban

Publications (2)

Publication Number Publication Date
JP2017523149A true JP2017523149A (ja) 2017-08-17
JP2017523149A5 JP2017523149A5 (enExample) 2018-06-21

Family

ID=53177487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574064A Pending JP2017523149A (ja) 2014-08-06 2015-05-13 エドキサバンの医薬組成物

Country Status (4)

Country Link
US (1) US20170231969A1 (enExample)
EP (1) EP3177290B1 (enExample)
JP (1) JP2017523149A (enExample)
WO (1) WO2016020080A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020004456A1 (ja) * 2018-06-27 2020-01-02 第一三共株式会社 ジアミン誘導体を含む顆粒剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3744320A1 (en) 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising edoxaban
EP3838267A1 (en) * 2019-12-19 2021-06-23 Biohorm, S.L. Edoxaban tablets
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols
AU2023390819A1 (en) 2022-12-09 2025-07-03 Synthon B.V. Formulation comprising edoxaban and preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026553A1 (en) * 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
WO2013089164A1 (ja) * 2011-12-14 2013-06-20 第一三共株式会社 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤
CN103919746A (zh) * 2014-04-17 2014-07-16 山东省医药工业研究所 依度沙班缓释片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY155256A (en) * 2009-06-18 2015-09-30 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved solubility
CN102791271B (zh) * 2010-03-19 2014-05-14 第一三共株式会社 抗凝剂的溶出改善方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026553A1 (en) * 2011-08-22 2013-02-28 Ratiopharm Gmbh Composition comprising edoxaban
WO2013089164A1 (ja) * 2011-12-14 2013-06-20 第一三共株式会社 高度腎機能障害を有する血栓塞栓症患者の血栓塞栓症の予防治療剤
CN103919746A (zh) * 2014-04-17 2014-07-16 山东省医药工业研究所 依度沙班缓释片及其制备方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020004456A1 (ja) * 2018-06-27 2020-01-02 第一三共株式会社 ジアミン誘導体を含む顆粒剤
JPWO2020004456A1 (ja) * 2018-06-27 2021-07-08 第一三共株式会社 ジアミン誘導体を含む顆粒剤
US11497741B2 (en) 2018-06-27 2022-11-15 Daiichi Sankyo Company, Limited Granules containing diamine derivative
JP7359764B2 (ja) 2018-06-27 2023-10-11 第一三共株式会社 ジアミン誘導体を含む顆粒剤

Also Published As

Publication number Publication date
EP3177290B1 (en) 2018-06-20
US20170231969A1 (en) 2017-08-17
WO2016020080A1 (en) 2016-02-11
EP3177290A1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
RU2456989C2 (ru) Твердые лекарственные формы, содержащие тадалафил
JP4785847B2 (ja) プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
JP6043281B2 (ja) ４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］−１ｈ−キノリン−２−オンラクテート一水和物を含む医薬組成物
CN101983054A (zh) 含有咪达那新的口腔内迅速崩解性片剂
WO2006082523A2 (en) Pharmaceutical sustained release composition of metformin
WO2020239986A1 (en) Pharmaceutical tablet composition comprising edoxaban
CN102655752A (zh) 包含整合酶抑制剂的固体药物组合物
WO2013026553A1 (en) Composition comprising edoxaban
TW202038917A (zh) 包含托法替尼或其藥學上可接受的鹽類的延長釋放配方及其製備方法
JP2020128429A (ja) レボカルニチンを含有する医薬錠剤
JP2017523149A (ja) エドキサバンの医薬組成物
EP2804588B1 (en) Method for producing cinacalcet compositions for direct tableting
CN1762357B (zh) 一种莫西沙星口服药物制剂及其制备方法
WO2009027786A2 (en) Matrix dosage forms of varenicline
EP3697392B1 (en) Tablets comprising tamsulosin and solifenacin
JP2022544167A (ja) ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用
WO2012107090A1 (en) Granulated composition comprising tadalafil and a disintegrant
KR101811700B1 (ko) 레보드로프로피진 함유 서방정 및 이의 제조방법
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
CN110913843B (zh) 药物组合物
KR101428149B1 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
WO2018130943A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP2009538905A (ja) 感湿性薬物を含んで成る安定性製剤及びその製造方法
WO2010112221A1 (en) Pharmaceutical compositions comprising memantine
WO2016042566A1 (en) Extended release formulation of trimetazidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180511

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190827